Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals
... SAN FRANCISCO, Dec. 10 /PRNewswire/ -- napo
Pharmaceuticals, Inc. ("Napo")
is pleased to annou... of $500,000 for the
purchase of 250,000 shares of napo
common stock; as well as regulatory and
sales mile...llaboration Agreement) will include a
reference to napo
as the licensor and will include Napo's logo and r...
Napo Obtains Special Protocol Assessment Agreement From FDA for Crofelemer
Pharmaceuticals, Inc., which focuses on the develo...r an FDA Fast Track designation. On Jan. 16, 2007, napo
met with the FDA under the Special Protocol Assess...ive design of its ADVENT trial. On March 14, 2007, napo
announced it had received approval from the princi...
Napo in Medical Technology
Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
... SAN FRANCISCO, Sept. 22 /PRNewswire/ -- napo
NAPL/NAPU) today announces p...tic, azithromycin, and rehydration therapy.
and ICDDR, B, upon receipt of additional funding, ...al
Institutes of Allergy and Infectious Disease.
is currently conducting a Phase 3 trial for crofel...
Napo Presents at ISPOR Meeting in Toronto
...um of anti-retroviral drugs. We are pleased
to see napo
taking the initiative to develop this new instrume...rhea."
For more information please contract:
Pharmaceuticals, Inc. Lisa Conte, Chief Executive...ector, Clinical Operations 1+ 760 918 5718 About napo
Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
travelers in Mexico and Jamaica with crofelemer, napo
is investigating the
regulatory pathway to file an...diarrhea in people living with HIV/AIDS (CRO-HIV). napo
is targeting an NDA
filing for CRO-HIV around the end of the year. napo
has exclusive worldwide
rights to crofelemer in al...
Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
...ritories, Glenmark will pay
ascending royalties to napo
on sales of crofelemer for these indications.
For more information please contact: napo
Pharmaceuticals, Inc. Lisa Conte, Chief Executive... 7466 5000 Tim Anderson, Mary-Jane Johnson About napo
Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from
2006 Presented at Digestive Disease Week in Washington, D.C.
...CO, Calif., May 23, 2007 /PRNewswire-FirstCall/
Pharmaceuticals, Inc., , which focuses on the deve...
licensed crofelemer for the d-IBS indication from napo
2004. Trine has worldwide development and ...
For more information please contact:
Lisa Conte, Chief Execut...
Napo in Biological Technology
Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
...MMD trial. This was partially offset by the absence of license income from napo
and the revenues lost from our withdrawal of IPLEX(TM) in the short stature...00,000 loss on investments represents the full write down on the prior year napo
investment during 2008.
As of December 31, 2008, we had total cash, ca...
Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
...m Napo, was recorded as part of our agreement with napo
For the nine months ended September 30,...ially offset by the absence of license income from napo
revenues lost from our withdrawal of IPLEX... investments represents the full write down of
investment during the first nine months of 2008.
Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)
NEW YORK, Sept. 25 /PRNewswire-USNewswire/ -- napo
Inc., ("Napo") of South San Franc...uch as
HIV/AIDS and cholera.
As part of the CAP, napo
and Direct Relief International ("DRI") have
formed an alliance whereby napo
will provide CRO-PED at cost for
Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
... absence of license income from our agreement with napo
Inc., ("Napo") from which we recei...ially offset by the absence of license income
and the revenues lost from our withdrawal of IPLEX...ss on
investments represents the write down on the napo
investment during the
first half of 2008.
Insmed Announces First Quarter 2008 Financial Results
...and Tercica Inc., and the absence of license income from our
agreement with napo
Pharmaceuticals Inc., ("Napo") from which we received a
milestone payment i...y a milestone
payment from Napo, was recorded as part of our agreement with napo
Interest income in the first quarter of 2008 at $279,000 was sli...
IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference
... Group Ltd.
Hoersholm, Denmark Santaris BioPharmaceutical Pharmaceutical
California, USA napo
Wurmlingen, Paradigm Spine, LLC Devices Germany
Tokyo, Japan EyePlusPlus,...
Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
...ng period of 2006. This increase was due to improvements
in the cost recovery from our EAP and the receipt of licensing income from
our agreement with napo
Pharmaceuticals Inc., ("NAPO"), combined with
increased sales of IPLEX(TM) during the first quarter of 2007.
The net loss for the 12 months ended De...
M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
...pany as Chief Medical Officer. Prior to joining
Ocera, Dr. Harris held the position of Chief Medical Officer and Vice
President of Clinical Affairs at napo
Pharmaceuticals. Dr. Harris has
extensive experience in gastrointestinal diseases as well as clinical and
"We are delighted b...